Edwards Lifesciences Corp (EW)vsIradimed Co (IRMD)
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
IRMD
Iradimed Co
$82.22
+0.43%
HEALTHCARE · Cap: $1.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 7443% more annual revenue ($6.51B vs $86.34M). IRMD leads profitability with a 26.7% profit margin vs 15.4%. EW appears more attractively valued with a PEG of 1.92. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
IRMD
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Margin of Safety
-67.7%
Fair Value
$61.47
Current Price
$82.22
$20.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Keeps 27 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Trading at 10.3x book value
0.3% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 26.7% and operating margin at 31.2%.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Revenue Growth, Market Cap. A P/E of 47.2x leaves little room for execution misses.
Key Dynamics to Monitor
EW profiles as a mature stock while IRMD is a value play — different risk/reward profiles.
IRMD carries more volatility with a beta of 0.90 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 48/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?